Zhu, Bin published the artcileStudy on the effect of parecoxib sodium on postoperative pain syndrome in patients after thoracotomy, Safety of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Xiandai Zhongxiyi Jiehe Zazhi (2015), 24(17), 1918-1919, database is CAplus.
The objective of this paper was to evaluate the effect of parecoxib sodium on postoperative pain syndrome in patients after thoracotomy. 96 Cases for thoracotomy were randomly and averagely divided into test group (giving parecoxib sodium and combined general and epidural anesthesia) and control group (giving physiol. saline and combined general and epidural anesthesia). The remifentanil dosage during thoracotomy, the dosage of opiates within 72 h after thoracotomy, adverse reaction incidence condition, pain incidence condition within 6 mo and pain duration in both group were compared. The morphine dosage within 72 h after thoracotomy in control group was (21.4±4.7) mg, while that in test group was 0 mg, and there was statistical difference (P<0.05). The incidence rates of gastrointestinal reaction and skin rash/itching in test group were lower than those in control group, and there was statistical difference (both P<0.05). The pain incidence within 6 mo and pain duration in test group were lower than those in control group, and there was statistical difference (both P<0.05). Parecoxib sodium could be used in thoracotomy, effectively reduce incidence of postoperative complications, and decrease the occurrence and duration of postoperative pain syndrome.
Xiandai Zhongxiyi Jiehe Zazhi published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C10H2F12NiO4, Safety of Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.
Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem